Buy RMD now and get great upside returns in a year or two, page-62

Your analysis makes good sense with clear rationality. In particular, the impact of GLP-1s on Obstructive Sleep Apnea (OSA) and subsequently on ResMed’s volumes is a core uncertainty for the years ahead. However, I remain confident that there are much more penetrations of continuous positive airway pressure (CPAP) therapy to people in developed and developing countries in particular.

Having noted the impact of GLP-1s on RMD share price, the price goes up and up as we are worrying and writing.

Looking at RSI (14 & 30 days line) technical indications, it is not in overbought territory yet.